US Edition10 Articles
10 Articles
All
Left
2
Center
2
Right
The Chandler Arizonan+8 Reposted by 8 other sources
Avidity Biosciences Reports First Quarter 2025 Financial Results and Recent Highlights
On track to deliver key regulatory updates for del-brax and topline data from dose escalation cohorts in the FORTITUDE™ trial in the second quarter
·Chandler, United States
Read Full Article
Avidity Biosciences (NASDAQ:RNA) Earns “Buy” Rating from Chardan Capital
Chardan Capital reissued their buy rating on shares of Avidity Biosciences (NASDAQ:RNA – Free Report) in a research report released on Wednesday morning,Benzinga reports. They currently have a $65.00 target price on the biotechnology company’s stock. A number of other analysts have also weighed in on the stock. Royal Bank of Canada reiterated an “outperform” […]
Coverage Details
Total News Sources10
Leaning Left2Leaning Right0Center2Last UpdatedBias Distribution50% Left, 50% Center
Bias Distribution
- 50% of the sources lean Left, 50% of the sources are Center
50% Center
L 50%
C 50%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage